|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017337,
umls-concept:C0019731,
umls-concept:C0030705,
umls-concept:C0030956,
umls-concept:C0278883,
umls-concept:C0332293,
umls-concept:C0449450,
umls-concept:C0677907,
umls-concept:C1441672,
umls-concept:C1510427,
umls-concept:C1718423,
umls-concept:C2700640
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1999-2-16
|
|
pubmed:abstractText |
Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0020-7136
|
|
pubmed:author |
pubmed-author:ArientiFF,
pubmed-author:AtzpodienJJ,
pubmed-author:BeauduinMM,
pubmed-author:BoonTT,
pubmed-author:BourlondAA,
pubmed-author:BrasseurFF,
pubmed-author:BrichardVV,
pubmed-author:CoulieP GPG,
pubmed-author:De GreveJJ,
pubmed-author:DietrichP YPY,
pubmed-author:DrénoBB,
pubmed-author:HumbletYY,
pubmed-author:JägerEE,
pubmed-author:KergerJJ,
pubmed-author:LiénardDD,
pubmed-author:MarchandMM,
pubmed-author:MasucciGG,
pubmed-author:ParmianiGG,
pubmed-author:RankinEE,
pubmed-author:RussoVV,
pubmed-author:TessierM HMH,
pubmed-author:VanwijckRR,
pubmed-author:WeynantsPP,
pubmed-author:van BarenNN,
pubmed-author:van der BruggenPP
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
18
|
|
pubmed:volume |
80
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
219-30
|
|
pubmed:dateRevised |
2007-7-24
|
|
pubmed:meshHeading |
pubmed-meshheading:9935203-Adult,
pubmed-meshheading:9935203-Aged,
pubmed-meshheading:9935203-Antigen Presentation,
pubmed-meshheading:9935203-Antigens, Neoplasm,
pubmed-meshheading:9935203-Disease Progression,
pubmed-meshheading:9935203-Female,
pubmed-meshheading:9935203-Genetic Code,
pubmed-meshheading:9935203-HLA-A1 Antigen,
pubmed-meshheading:9935203-Humans,
pubmed-meshheading:9935203-Immunotherapy,
pubmed-meshheading:9935203-Male,
pubmed-meshheading:9935203-Melanoma,
pubmed-meshheading:9935203-Middle Aged,
pubmed-meshheading:9935203-Neoplasm Proteins,
pubmed-meshheading:9935203-Remission Induction
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
|
|
pubmed:affiliation |
Ludwig Institute for Cancer Research, Brussels Branch, and Université Catholique de Louvain, Belgium. marchand@licr.ucl.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|
